Clinical Trials
1
Active:0
Completed:1
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia
Phase 2
Completed
- Conditions
- Hyperlipidemia
- Interventions
- Drug: XueZhiKang (XZK), a botanic product with multiple componentsDrug: Placebo
- First Posted Date
- 2011-04-01
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- Beijing Peking University WBL Biotech Co., Ltd.
- Target Recruit Count
- 116
- Registration Number
- NCT01327014
- Locations
- 🇺🇸
Robert Karns, MD A Medical Corporation, Beverly Hills, California, United States
🇺🇸Jellinger and Lerman, MD, Hollywood, Florida, United States
🇺🇸Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, United States
News
No news found